BR112023020659A2 - Métodos para controlar a atividade de célula imune - Google Patents

Métodos para controlar a atividade de célula imune

Info

Publication number
BR112023020659A2
BR112023020659A2 BR112023020659A BR112023020659A BR112023020659A2 BR 112023020659 A2 BR112023020659 A2 BR 112023020659A2 BR 112023020659 A BR112023020659 A BR 112023020659A BR 112023020659 A BR112023020659 A BR 112023020659A BR 112023020659 A2 BR112023020659 A2 BR 112023020659A2
Authority
BR
Brazil
Prior art keywords
cellular immunotherapy
methods
target antigen
immune cell
individual
Prior art date
Application number
BR112023020659A
Other languages
English (en)
Portuguese (pt)
Inventor
Alexander Barden Julian
Patrick Schlegel
Ziduo Li
Original Assignee
Biosceptre Aust Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021901030A external-priority patent/AU2021901030A0/en
Application filed by Biosceptre Aust Pty Ltd filed Critical Biosceptre Aust Pty Ltd
Publication of BR112023020659A2 publication Critical patent/BR112023020659A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112023020659A 2021-04-08 2022-04-08 Métodos para controlar a atividade de célula imune BR112023020659A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2021901030A AU2021901030A0 (en) 2021-04-08 Methods for controlling immune cell activity
PCT/AU2022/050311 WO2022213154A1 (en) 2021-04-08 2022-04-08 Methods for controlling immune cell activity

Publications (1)

Publication Number Publication Date
BR112023020659A2 true BR112023020659A2 (pt) 2023-12-05

Family

ID=83544929

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020659A BR112023020659A2 (pt) 2021-04-08 2022-04-08 Métodos para controlar a atividade de célula imune

Country Status (9)

Country Link
US (1) US20250282844A1 (https=)
EP (1) EP4319793A4 (https=)
JP (1) JP2024513485A (https=)
CN (1) CN117157092A (https=)
AU (1) AU2022253547A1 (https=)
BR (1) BR112023020659A2 (https=)
CA (1) CA3213042A1 (https=)
MX (1) MX2023011807A (https=)
WO (1) WO2022213154A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024232401A1 (en) * 2023-03-08 2025-08-21 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors for binding to dysfunctional p2x 7 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4384852B2 (ja) * 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
CN100497386C (zh) * 2001-09-03 2009-06-10 因特里特有限公司 非功能性p2x7受体的抗体及其应用
CN102143978B (zh) * 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
US10858415B2 (en) * 2014-01-29 2020-12-08 Tron—Translationale Onkologie An Der Universitatsmedizin Der Johannes Guttenberg-Universitat Mainz Gemeinnuizige Gmbh Peptide mimotopes of claudin 18.2 and uses thereof
SG11201900344YA (en) * 2016-07-15 2019-02-27 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2019022796A1 (en) * 2017-07-26 2019-01-31 Panoramic Power Ltd. SYSTEM AND METHOD FOR TIME SYNCHRONIZATION OF SELF-POWERED POWER SENSOR
EP4304610A4 (en) * 2021-03-11 2025-03-05 Biosceptre (Aust) Pty Ltd Novel cell therapy system

Also Published As

Publication number Publication date
AU2022253547A1 (en) 2023-10-05
WO2022213154A1 (en) 2022-10-13
EP4319793A4 (en) 2025-03-19
EP4319793A1 (en) 2024-02-14
CN117157092A (zh) 2023-12-01
US20250282844A1 (en) 2025-09-11
JP2024513485A (ja) 2024-03-25
MX2023011807A (es) 2024-01-05
CA3213042A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
BR112022020256A2 (pt) “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
BR112022015374A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
BR112012017124A2 (pt) método de modificação polipeptídica para purificação de multímeros polipeptídicos
BRPI0413314A (pt) antìgeno quimérico para provocar uma resposta imune, métodos para realçar a apresentação de antìgeno em uma célula que apresenta antìgeno, para ativar uma célula que apresenta antìgeno, para provocar uma resposta imune, para quebrar a toleráncia, e para tratar uma condição imuno-tratável, composição farmacêutica, artigo de fabricação, método para produzir um antìgeno quimérico, polinucleotìdeo, microorganismo ou linhagem celular, e, vetor
BRPI0507433B8 (pt) anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit
BR112022020706A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
BR112021024553A2 (pt) Molécula de ligação específica para cd73 e uso de molécula de ligação
MX2021007947A (es) Terapeuticos de anticuerpo que se unen a ctla4.
NZ734803A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
MX2021011633A (es) Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
BR112017018770A2 (pt) redução da tolerância imunológica induzida por pd-l1
PT1819830E (pt) Métodos para engenharia de anticorpos
BR112012012912A2 (pt) anticorpo ou fragmento do mesmo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo e métodos in vitro para neutralizar il-10 em uma amostra e para detectar a presença de il-10 em uma amostra.
NO20090069L (no) Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
NZ785401A (en) Anti-ms4a4a antibodies and methods of use thereof
WO2022032003A3 (en) Anti-claudin 18.2 antibodies and uses thereof
BR112023020659A2 (pt) Métodos para controlar a atividade de célula imune
ZA202201464B (en) Anti-tigit antibodies and application thereof
MY189412A (en) Antibody to programmed cell death 1 (pd-1) and use thereof
MY210018A (en) Monoclonal antibody that binds specifically to gitr
BR112022010179A2 (pt) Anticorpos anti-vírus da febre amarela, e métodos de sua geração e uso
BR112021017860A2 (pt) Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica
BR112023006989A2 (pt) Anticorpos biespecíficos anti-pd-1/cd40 e usos dos mesmos
MX2022014243A (es) Proteina de union al antigeno st2.